Vitamin D Content and the State of Bone Metabolism in Patients with Syndrome of Hyperthyroidism (Review of Literature)

І.V. Pankiv

Abstract


The literature review presents data of researches on the content of vitamin D and the state of bone metabolism in patients with syndrome of hyperthyroidism. Overt hyperthyroidism is associated with accelerated bone remodeling, reduced bone density, osteoporosis, and an increase in fracture rate. Summarizing the results of the studies conducted by different authors, there should be noted the value of normal balance of thyroid hormones for a skeletogeny and providing bone mineral density.


Keywords


hyperthyroidism; vitamin D; bone tissue; review

References


Povorozniuk VV. Diseases of the bone and muscle system in people of different age. К., 2009. 664 s. (Ukrainian)

Gorka J, Taylor-Gjevre RM, Arnason T. Metabolic and clinical consequences of hyperthyroidism on bone density. Int. J. Endocrinol. 2013: 638727. Published online 2013 Jul 22. doi: 10.1155/2013/638727.

Мasalova NN, Zaharenko RV. State of phosphoric and calcium exchange and bone metabolism in normal conditions and in patients with thyroid disorders. Dalnevostochnyi meditsinslkiy zhurnal.2009;2:122-125. (Russian)

Lee MS, Kim SY, Lee MC. et al. Negative correlation between the change in bone mineral density and serum osteocalcin in patients with hyperthyroidism. Journal of Clinical Endocrinology and Metabolism. 1990;70(3):766-770.

Svare A, Nilsen TIL, Bjøro T. et al. Hyperthyroid levels of TSH correlate with low bone mineral density: the HUNT 2 study. European Journal of Endocrinology. 2009;161(5):779-786.

Cummings SR, Nevitt MC, Browner WS. et al. Risk factors for hip fracture in white women. New England Journal of Medicine. 1995;332(12):767-773.

Bauer DC, Ettinger B, Nevitt MC, Stone KL. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Annals of Internal Medicine. 2001;134(7):561-568.

Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. Journal of Biological Chemistry. 2010;285(33):25103-25108.

Boyce BF. Advances in the regulation of osteoclasts and osteoclast functions. J Dent Res. 2013;92(10):860-867.

Melsen F, Mosekilde L. Trabecular bone mineralization lag time determined by tetracycline double-labeling in normal and certain pathological conditions. Acta Pathologica et Microbiologica Scandinavica. 1980;88(2):83-88.

Harvey CB, O’Shea PJ, Scott AJ. et al. Molecular mechanisms of thyroid hormone effects on bone growth and function. Molecular Genetics and Metabolism. 2002;75(1):17-30.

Diedukh NV, Pobel EA. Bone tissue in normal conditions and in patients with osteoporosis: preparations of calcium and vitamin D (review of literature). Ortopedia, travmatologia i protezirovanie. 2013;3:92-98. (Russian)

Ornitz DM, Marie PJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev. 2002;16(12):1446-1465.

Yasuda T, Okamoto Y, Hamada N. et al. Serum vitamin D levels are decreased and associated with thyroid volume in female patients with newly onset Graves’ disease. Endocrine. 2012;42(3):739-741.

Greenspan SLS, Greenspan FS. The effect of thyroid hormone on skeletal integrity. Annals of Internal Medicine. 1999;130(9):750-758.

Greenlund LJS, Nair KS, Brennan MD. Changes in body composition in women following treatment of overt and subclinical hyperthyroidism. Endocrine Practice. 2008;14(8):973-978.

Zhang H, Liang L, Xie Z. Low vitamin D status is associated with increased thyrotropin-receptor antibody titer in Graves’ disease. Endocr. Pract. 2015;21:258-263.

Vestergaard P, Rejnmark L, Weeke J, Mosekilde L. Fracture risk in patients treated for hyperthyroidism. Thyroid. 2000;10(4):341-348.

Vestergaard P, Mosekilde L. Hyperthyroidism, bone mineral, fracture risk – a meta-analysis. Thyroid. 2003;13(6):585-593.

Karga H, Papapetrou PD, Korakovouni A. et al. Bone mineral density in hyperthyroidism. Clinical Endocrinology. 2004;61(4):466-472.

Lakatos P. Thyroid hormones: beneficial or deleterious for bone? Calcified Tissue International. 2003;73(3):205-209.

Siddiqi A, Burrin JM, Noonan K. et al. A longitudinal study of markers of bone turnover in Graves’ disease and their value in predicting bone mineral density. Journal of Clinical Endocrinology and Metabolism. 1997;82(3):753-759.

Udayakumar N, Chandrasekaran M, Rasheed MH. et al. Evaluation of bone mineral density in thyrotoxicosis. Singapore Medical Journal. 2006;47(11):947-950.

Jódar E, Muñoz-Torres M, Escobar-Jiménez F. et al. Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of aetiology and menopause. Clinical Endocrinology.1997;47(3):279-285.

Langdahl BL, Loft AGR, Eriksen EF. et al. Bone mass, bone turnover and body composition in former hypothyroid patients receiving replacement therapy. European Journal of Endocrinology. 1996;134(6):702-709.

Murphy E, Bassett JHD, Williams GR. Disorders of calcium. Practitioner. 2006;250(1686):4-8.

Zeni S, Gomez-Acotto C, Mautalen C. The effect of olpadronate in ovariectomized thyroxine-treated rats. Bone.1997;21(4):329-333.

Lupoli G, Nuzzo V, Di Carlo C. et al. Effects of alendronate on bone loss in pre- and postmenopausal hyperthyroid women treated with methimazole. Gynecological Endocrinology. 1996;10(5):343-348.

Fittipaldi MR, Fonderico F, Vitale G. et al. Osteoporosis treatment in elderly hyperthyroid male patients. Journal of Endocrinological Investigation. 2002;25(10):98-100.

Majima T, Komatsu Y, Doi K. et al. Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves’ disease. Journal of Bone and Mineral Metabolism. 2006;24(2):105-113.

Dhanwal DK, Gupta N. Bone mineral density trends in Indian patients with hyperthyroidism – effect of antithyroid therapy. Journal of Association of Physicians of India. 2011;59(9):561-567.

Cooper DS, Biondi B. Subclinical thyroid disease. The Lancet. 2012;379(9821):1142-1154.

Grimnes G, Emaus N, Joakimsen RM. et al. The relationship between serum TSH and bone mineral density in men and postmenopausal women: the Tromsø study. Thyroid. 2008;18(11):1147-1155.

Lee WY, Oh KW, Rhee EJ. et al. Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women. Archives of Medical Research. 2006;37(4):511-516.

Foldes J, Tarjan G, Szathmari M. et al. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis? Clinical Endocrinology. 1993;39(5):521-527.

Tauchmanovà L, Nuzzo V, Del Puente A. et al. Reduced bone mass detected by bone quantitative ultrasonometry and DEXA in pre- and postmenopausal women with endogenous subclinical hyperthyroidism. Maturitas. 2004;48(3):299-306.

Rosario PW. Bone and heart abnormalities of subclinical hyperthyroidism in women below the age of 65 years. Arquivos Brasileiros de Endocrinologia e Metabologia. 2008;52(9):1448-1451.

Lee JS, Bůžková P, Fink HA. et al. Subclinical thyroid dysfunction and incident hip fracture in older adults. Archives of Internal Medicine. 2010;170(21):1876-1883.

Vadiveloo T, Donnan PT, Cochrane L, Leese GP. The thyroid epidemiology, audit, and research study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. Journal of Clinical Endocrinology and Metabolism. 2011;96(5):1344-1351.

Parle JV, Franklyn JA, Cross KW. et al. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clinical Endocrinology. 1991;34(1):77-83.

Hanna FW, Pettit RJ, Ammari F. et al. Effect of replacement doses of thyroxine on bone mineral density. Clinical Endocrinology. 1998;48(2):229-234.

Heemstra KA, Hamdy NAT, Romijn JA, Smit JWA. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid. 2006;16(6):583-591.

Cipriani C, Romagnoli E, Scarpiello A. et al. Phalangeal quantitative ultrasound and bone mineral density in evaluating cortical bone loss: a study in postmenopausal women with primary hyperparathyroidism and subclinical iatrogenic hyperthyroidism. Journal of Clinical Densitometry. 2009;12(4):456-460.

Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. European Journal of Endocrinology. 1994;130(4):350-356.

Uzzan B, Campos J, Cucherat M. et al. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. Journal of Clinical Endocrinology and Metabolism. 1996;81(12):4278-4289.

Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. European Journal of Endocrinology. – 1994. – Vol.130(4). – P.350-356.

Heemstra KA, Hamdy NAT, Romijn JA, Smit JWA. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid. 2006;16(6):583-591.

Nicholls JJ, Brassill MJ, Williams GR., Williams JHD. The skeletal consequences of thyrotoxicosis. The Journal of Endocrinology. 2012;213:209-221.

Bauer DC, Ettinger B, Nevitt MC, Stone KL. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Annals of Internal Medicine. 2001;134(7):561-568.

Flynn RW, Bonellie SR, Jung RT. et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. Journal of Clinical Endocrinology and Metabolism. 2010;95(1):186-193.

Appetecchia M. Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study. Hormone Research. 2005;64(6):293-298.

Wang LY, Smith AW, Palmer FL. et al. Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. Thyroid. 2015;25(3):300-307.

Kung AWC, Yeung SS. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. Journal of Clinical Endocrinology and Metabolism. 1996;81(3):1232-1236.

Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen. Journal of the American Medical Association. 1994;271(16):1245-1249.

Оliynyk VA, Povorozniuk VV, Terekhova GM. Secondary osteoporosis in patients with endocrine pathology. Problemy osteologii. 1998;1(1):51-57 (Ukrainian).

Anderson GL, Limacher M. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health initiative randomized controlled trial. Journal of the American Medical Association. 2004;291(14):1701-1712.

Rosen HN, Moses AC, Garber J. et al. Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. Journal of Clinical Endocrinology and Metabolism. 1998;83(7):2324-2330.

Аnvarova SS, Niyazova NF. Estimation of the state of bone tissue in women with hyperthyroidism, in the conditions of iodine deficiency. Doklady Akademii nauk Respubliki Tadjikistan. 2010;53(11):889-892. (Russian).




DOI: https://doi.org/10.22141/2224-0721.7.79.2016.86418

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2018

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru